Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. TECNIS PureSee IOL delivers clarity of vision for patients, with 97% of them reporting no very bothersome visual disturbances. TECNIS PureSee IOL will be available for patients in the U.S. later this year.
“Today marks an exciting milestone for people living with cataracts. The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs,” said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson.
“Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”
Currently, an estimated 94 million people aged 50 years and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery.
JNJ shares lost $2.02 to $240.97.
